STOCK TITAN

Alector to Participate at the BofA Securities 2022 Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Alector, a clinical-stage biotechnology company focused on immuno-neurology, announced its participation in the BofA Securities 2022 Healthcare Conference. The event will occur on May 12, 2022, at 11:20 a.m. PT, and will feature a fireside chat with management. A live webcast can be accessed through the Alector website, with a replay available for 90 days post-event. Alector specializes in therapeutic approaches for neurodegenerative diseases, targeting immune dysfunction in conditions such as Alzheimer's and frontotemporal dementia.

Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Thursday, May 12, 2022, at 11:20 a.m. PT.

A live webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 90 days following the event.

About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

Contacts:

1AB (media)
Dan Budwick
973-271-6085
dan@1abmedia.com 

Argot Partners (investors)
Eric Kasper/Carrie McKim
Argot Partners
212.600.1902
alector@argotpartners.com 


FAQ

What is the date and time of Alector's participation in the BofA Securities 2022 Healthcare Conference?

Alector will participate on May 12, 2022, at 11:20 a.m. PT.

Where can I watch the Alector fireside chat?

The fireside chat will be available via a live webcast on Alector's 'Events & Presentations' page.

How long will the Alector conference replay be available?

The replay will be available for 90 days following the event.

What is Alector's focus in biotechnology?

Alector focuses on immuno-neurology, targeting immune dysfunction in neurodegenerative diseases.

Which neurodegenerative diseases does Alector target?

Alector targets conditions like Alzheimer's disease and frontotemporal dementia.

Alector, Inc.

NASDAQ:ALEC

ALEC Rankings

ALEC Latest News

ALEC Stock Data

169.42M
88.17M
9.97%
86.08%
4.11%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SOUTH SAN FRANCISCO